Colorectal Cancer Clinical Trials in Tennessee

Showing 301-312 of 312 trials

Study of XL281 in Adults With Solid Tumors

NCT00451880

The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.

CancerNon-small-cell Lung CancerColorectal Cancer+2 more

Exelixis180 participantsStarted Feb 2007

Scottsdale, Arizona, United States • Tampa, Florida, United States • Detroit, Michigan, United States +3 more locations

COMPLETEDPhase 229 miles

Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

NCT00193167

This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.

Colon Cancer

SCRI Development Innovations, LLC40 participantsStarted Jan 2004

Nashville, Tennessee, United States

UNKNOWNPhase 386 miles

Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

NCT00337389

To compare the progression-free survival time (PFS) in patients treated with 5-FU modulated with CoFactor (plus bevacizumab) to 5-FU modulated with leucovorin (plus bevacizumab) in patients with Metastatic Colorectal Cancer.

Metastatic Colorectal CancerColon CancerRectal Cancer

Mast Therapeutics, Inc.1,200 participantsStarted May 2006

Florence, Alabama, United States • Anaheim, California, United States • Apple Valley, California, United States +44 more locations

Study of XL281 in Adults With Solid Tumors

Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer

Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.

Colorectal Cancer Trials in Other Cities

Patient-Reported Outcomes in Long-Term Survivors of Colon and Rectal Cancers

SWOG-S9635 Fluorouracil Plus Ethynyluracil in Advanced Colorectal Cancer Not Responded to Fluorouracil

A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors

DHA-Paclitaxel in Treating Patients With Metastatic Colorectal Cancer

S9923 R115777 in Treating Patients With Advanced Colorectal Cancer

A Study of ABT-751 in Patients With Colorectal Cancer

GM-CT-01 Plus 5-Fluorouracil as Third- or Fourth-Line Therapy for Metastatic Colorectal Cancer

Photodynamic Therapy System for Patients With Refractory/Unresponsive Solid Tumors

Study of Oxaliplatin, Capecitabine, and Bevacizumab to Treat Older Patients With Colorectal Cancer

Other Conditions in Tennessee